<DOC>
	<DOCNO>NCT00774007</DOCNO>
	<brief_summary>Emerging evidence indicate presence low-grade mucosal inflammation pathogenetic role IBS . The aim pilot study provide mesalazine treatment IBS patient reduce low grade colonic inflammation .</brief_summary>
	<brief_title>A Randomized Controlled Pilot Trial Mesalazine Patients With Irritable Bowel Syndrome</brief_title>
	<detailed_description>Emerging evidence indicate presence low-grade mucosal inflammation pathogenetic role IBS . The aim pilot study provide mesalazine treatment IBS patient reduce low grade colonic inflammation . This pilot double blind placebo control study . A total twenty patient ( male female ) recruit ; ten randomly assign placebo control arm ten study medication arm . Inclusion criterion : - IBS patient ( male female ) positive diagnosis base Rome II criterion [ 20 ] - age ≥ 18 year - Patients capable conform study protocol ; - Patients give free inform consent Exclusion criterion : - Patients ascertain Inflammatory Bowel Diseases ( Crohn disease , Diverticular disease , Ulcerative colitis , Infectious colitis , Ischemic colitis , microscopic colitis ) ; food intolerance/allergy ; active malignancy type , history malignancy ; presence major abdominal surgery ; ascertain hypersensitivity salicylates ; positive faecal culture bacterial , mycotic parasitic pathogen ; patient history clinically significant renal ( creatinine ≥ 2.0 mg/dL ≥177 μmol/L ) , hepatic ( AST ALT great three time upper limit normal range ) , cardiac , metabolic haematological disease ; esophageal , gastric duodenal ulcer within 30 day prior randomization ; patient intend ascertained pregnancy ; lactation ; patient become unable conform protocol ; patient continuously take laxative ; patient antibiotic therapy last month ; patient current therapy corticosteroid ; treatment investigational drug within previous 30 day ; treatment lactulose compound lower colonic pH prevent release active moiety ; recent history suspicion alcohol abuse drug addiction ; severe pathology interfere treatment clinical test trial ; previous participation study . Treatments : Mesalazine cpr 800 mg t.i.d . 8 week Placebo cpr t.i.d . 8 week Primary End Points : The primary end point study assess effect mesalazine treatment : • Total number inflammatory mucosal cell Secondary End Points : - Individual inflammatory cell subset enterochromaffin ( EC ) cell colonic mucosa ( mast cell , macrophage , B T lymphocytes subset ) - Inflammatory release mucosal biopsies - Indicative measure symptom relief The local tolerability treatment , daily monitoring intolerance manifestation gastrointestinal level , carry patient report investigator control visit . Adverse event ( ) concurrent illness ( e ) occur study monitor . The following laboratory test result record Basal Visit ( T0 ) end study ( T8 ) : • Hemochrome , AST , ALT , creatinine , γ-GT , alkaline phosphatase ( AP ) , total bilirubin , glucose , N , Na+ , K+ , Ca 2+ Urine pregnancy test : patient female childbearing potential , urine pregnancy test perform must confirm negative first dose study medication administer . On BASAL VISIT ( T0 ) follow perform : 1 . Diagnosis IBS disease base Rome II criteria 2 . Check inclusion exclusion criterion 3 . Written Consent 4 . Record medical history concomitant medication 5 . Physical examination 6 . Urine pregnancy test 7 . Vital Signs ( BP , HR , LR ) 8 . Fecal Culture 9 . Sigmoid biopsy 10 . Delivery patient 's diary 11 . Laboratory Assessments 12 . Symptom questionnaire On VISITS T2 , T4 T6 ( 2 , 4 6 week ) follow perform : 1 . Symptom questionnaire 2 . Vital Signs ( BP , HR , LR ) 3 . Collection/Delivery patient 's diary 4 . Record Adverse Events 5 . Record Concomitant Medication On VISIT T8 FINAL VISIT ( After eight week ) follow perform : 1 . Sigmoid biopsy 2 . Symptom questionnaire 3 . Collection/Delivery patient 's diary 4 . Physical examination 5 . Laboratory Assessments 6 . Vital Signs ( BP , HR , LR ) 7 . Record Adverse Events 8 . Record Concomitant Medication Data record study summarise treatment group compare use descriptive statistic .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>IBS patient ( male female ) positive diagnosis base Rome II criterion age ≥ 18 year Patients capable conform study protocol ; Patients give free informed consent Patients ascertain Inflammatory Bowel Diseases ( Crohn disease , Diverticular disease , Ulcerative colitis , Infectious colitis , Ischemic colitis , microscopic colitis ) Patients ascertain food intolerance/allergy Patients active malignancy type , history malignancy ( patient history malignancy surgically remove evidence recurrence least five year study enrollment also acceptable ) Presence major abdominal surgery Ascertained hypersensitivity salicylates Positive faecal culture bacterial , parasitic pathogen Patients history clinically significant renal ( creatinine ≥ 2.0 mg/dL ≥177 μmol/L ) , hepatic ( AST ALT great three time upper limit normal range ) , cardiac , metabolic haematological disease Esophageal , gastric duodenal ulcer within 30 day prior randomization Patients intend ascertained pregnancy ; lactation Patients become unable conform protocol Patients continuously take laxative Patients antibiotic therapy last month Patients current therapy corticosteroid Treatment investigational drug within previous 30 day Treatment lactulose compound lower colonic pH prevent release active moiety Recent history suspicion alcohol abuse drug addiction Any severe pathology interfere treatment clinical test trial Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Irritable bowel syndrome , abdominal pain , abdominal bloating , immune cell , mast cell</keyword>
</DOC>